The biggest modern breakthrough for cancer treatment has been antibody therapies. An increasing number of biotechnology companies have antibody - or vaccine-based cancer therapies in development. This course aims to attract students interested in tumour immunology who wish to pursue a career either in industry (biotechnology) or academia.
The course covers both antibody and vaccine cancer therapies and explores the immunology of the tumour host interface. In addition, students will learn about intellectual property and how to exploit scientific research in scientific writings, patents and in development of business plans applicable to the biotechnology industry. To gain practical experience in research, students will carry out a research project in the field of tumour immunology.
The MSc Cancer Immunology and Biotechnology is taught on a full-time basis over one year (September to late August).
You will take 120 credits worth of taught modules, as well as a 60-credit research module which will enable you to experience contemporary research methods by designing a research programme and performing experiments, surveys, or other research activities aimed at solving a specific biomedical problem.
For a more extensive overview, please visit the course page on the University of Nottingham's online prospectus.
